Zhou Yonglin, Guo Yan, Sun Xiaodi, Ding Rui, Wang Yanling, Niu Xiaodi, Wang Jianfeng, Deng Xuming
Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun 130062, China.
Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun 130021, Jilin, China.
ACS Omega. 2020 May 12;5(20):11424-11438. doi: 10.1021/acsomega.0c00460. eCollection 2020 May 26.
The rapid spread of β-lactamase-producing bacteria in clinical practice has increasingly deteriorated the performance of β-lactam antibiotics against such resistant strains. Thus, novel agents or strategies for the war against β-lactamase-producing bacteria, especially hypervirulent resistant bacteria (such as toxin-secreting ) carrying complex β-lactamases, are urgently needed. In this study, we found that the natural compound oleanolic acid (OA) and its analogues (especially corosolic acid (CA)) significantly inhibited the activity of important β-lactamases (NDM-1, KPC-2, and VIM-1) in Enterobacteriaceae and β-lactamases (β-lactamase N1) in . The results showed significant synergy with β-lactams against β-lactamase-positive bacteria (fractional inhibitory concentration (FIC) index <0.5). Additionally, OA treatment significantly inhibited the activity of hemolysin from various bacteria. In the mouse infection models, the combined therapy with OA and β-lactams exhibited a significant synergistic effect in the treatment of β-lactamase-producing bacteria, as evidenced by the survival rate of - or -infected mice, which increased from 25.0 to 75.0% or from 44.4 to 61.1% (CA increased to 77.8%), respectively, compared to treatment with individual β-lactams. Although OA treatment alone led to systemic protection against -infected mice by directly targeting α-hemolysin (Hla), a relatively better therapeutic effect was observed for the combined therapy. To the best of our knowledge, this study is the first to find effective inhibitors against resistant bacterial infections with a two-pronged strategy by simultaneously targeting resistance enzymes and toxins, which may provide a promising therapeutic strategy for drug-resistant bacterial infections.
产β-内酰胺酶细菌在临床实践中的迅速传播,日益降低了β-内酰胺类抗生素对这类耐药菌株的疗效。因此,迫切需要对抗产β-内酰胺酶细菌,特别是携带复杂β-内酰胺酶的高毒力耐药细菌(如分泌毒素的细菌)的新型药物或策略。在本研究中,我们发现天然化合物齐墩果酸(OA)及其类似物(尤其是科罗索酸(CA))能显著抑制肠杆菌科中重要的β-内酰胺酶(NDM-1、KPC-2和VIM-1)以及[此处原文缺失相关细菌名称]中的β-内酰胺酶(β-内酰胺酶N1)的活性。结果显示,其与β-内酰胺类药物联合使用时,对β-内酰胺酶阳性细菌具有显著的协同作用(分数抑菌浓度(FIC)指数<0.5)。此外,OA处理能显著抑制多种细菌溶血素的活性。在小鼠感染模型中,OA与β-内酰胺类药物联合治疗在治疗产β-内酰胺酶细菌方面表现出显著的协同效应,这可通过[此处原文缺失相关细菌名称]或[此处原文缺失相关细菌名称]感染小鼠的存活率得到证明,与单独使用β-内酰胺类药物治疗相比,存活率分别从25.0%提高到75.0%或从44.4%提高到61.1%(CA提高到77.8%)。尽管单独使用OA治疗可通过直接靶向α-溶血素(Hla)对[此处原文缺失相关细菌名称]感染的小鼠产生全身保护作用,但联合治疗的疗效相对更好。据我们所知,本研究首次通过同时靶向耐药酶和毒素的双管齐下策略,发现了针对耐药细菌感染的有效抑制剂,这可能为耐药细菌感染提供一种有前景的治疗策略。